Phospholipase C-dependent hydrolysis of phosphatidylinositol 4,5-bisphosphate underlies agmatine-induced suppression of N-type Ca2+ channel in rat celiac ganglion neurons

PIP2 alters of Ca2+ currents in acutely dissociated supraoptic oxytocin neurons

Magnocellular neurosecretory cells (MNCs) occupying the supraoptic nucleus (SON) contain voltage‐gated Ca²⁺ channels that provide Ca²⁺ for triggering vesicle release, initiating signaling pathways, and activating channels, such as the potassium channels underlying the afterhyperpolarization (AHP). Phosphotidylinositol 4,5‐bisphosphate (PIP₂) is a phospholipid membrane component that has been previously shown to modulate Ca²⁺ channels, including in the SON in our previous work. In this study, we further investigated the ways in which PIP₂ modulates these channels, and for the first time show how PIP₂ modulates Ca_V channel currents in native membranes. Using whole cell patch clamp of genetically labeled dissociated neurons, we demonstrate that PIP₂ depletion via wortmannin (0.5 μmol/L) inhibits Ca²⁺ channel currents in OT but not VP neurons. Additionally, it hyperpolarizes voltage‐dependent activation of the channels by ~5 mV while leaving the slope of activation unchanged, properties unaffected in VP neurons. We also identified key differences in baseline currents between the cell types, wherein VP whole cell Ca²⁺ currents display more inactivation and shorter deactivation time constants. Wortmannin accelerates inactivation of Ca²⁺ channels in OT neurons, which we show to be mostly an effect on N‐type Ca²⁺ channels. Finally, we demonstrate that wortmannin prevents prepulse‐induced facilitation of peak Ca²⁺ channel currents. We conclude that PIP₂ is a modulator that enhances current through N‐type channels. This has implications for the afterhyperpolarization (AHP) of OT neurons, as previous work from our laboratory demonstrated the AHP is inhibited by wortmannin, and that its primary activation is from intracellular Ca²⁺ contributed by N‐type channels.

Cardiovascular Effects Mediated by Imidazoline Drugs: An Update

OBJECTIVE

Clonidine is a centrally acting antihypertensive drug. Hypotensive effect of clonidine is mediated mainly by central α2-adrenoceptors and/or imidazoline receptors located in a complex network of the brainstem. Unfortunately, clonidine produces side effects such as sedation, mouth dry, and depression. Moxonidine and rilmenidine, compounds of the second generation of imidazoline drugs, with fewer side effects, display a higher affinity for the imidazoline receptors compared with α2-adrenoceptors. The antihypertensive action of these drugs is due to inhibition of the sympathetic outflow primarily through central I1-imidazoline receptors in the RVLM, although others anatomical sites and mechanisms/receptors are involved. Agmatine is regarded as the endogenous ligand for imidazoline receptors. This amine modulates the cardiovascular function. Indeed, when administered in the RVLM mimics the hypotension of clonidine.

RESULTS

Recent findings have shown that imidazoline drugs also exert biological response directly on the cardiovascular tissues, which can contribute to their antihypertensive response. Currently, new imidazoline receptors ligands are in development.

CONCLUSION

In the present review, we provide a brief update on the cardiovascular effects of clonidine, moxonidine, rilmenidine, and the novel imidazoline agents since representing an important therapeutic target for some cardiovascular diseases.